Sanofi reaffirms its India pharma bet with a 1,068 crore stake purchase, strengthening its local presence through an internal ownership shift.
AI drug discovery is gaining ground in India's pharmaceutical R&D landscape, with Rasayan Labs and ICT Mumbai bringing computational chemistry, molecular design and synthesis planning into a unified drug-discovery workflow.
Roche bets USD 2 billion on oral heart and metabolic pills through a discovery collaboration with Atavistik Bio targeting chronic diseases.
Diabetes care advances with new insulin, a new trial, and fresh funding, expanding treatment options for type 2 diabetes.
InnoCare and Eli Lilly have signed drug discovery pacts worth up to 3.35 billion, strengthening global interest in Chinese innovation.
Karnataka seeks wider medical device price controls as it flags unfair trade margins and rising healthcare costs for patients.
An FDA panel backed GRAIL's Galleri test, raising big questions for liquid biopsy and India's cancer care.
EU regulators extend single-inhaler triple therapy access to teenagers with asthma, giving patients aged 12 and older a new maintenance option.
Claude AI uncovers a novel enzyme system with CRISPR-like features, marking Anthropic’s first public biology research result and expanding AI-driven biological discovery.
Today in Pharma highlights major deals and alliances, from Novartis’ radioligand therapy agreement with BoomRay to IMA and Abbott’s adult immunization drive.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")